EAM Investors’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

EAM Investors’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-276,250	Closed	-$2.92M	–	386
2022 Q4	$2.92M	Buy	+276,250	New	+$2.23M	0.6%	42
2020 Q3	–	Sell	-54,020	Closed	-$762K	–	375
2020 Q2	$762K	Sell	54,020 -56,524	-51%	-$714K	0.17%	221
2020 Q1	$1.02M	Buy	+110,544	New	+$1.42M	0.32%	147
2019 Q4	–	Sell	-14,126	Closed	-$96K	–	336
2019 Q3	$96K	Sell	14,126 -44,567	-76%	-$451K	0.03%	229
2019 Q2	$710K	Buy	+58,693	New	+$319K	0.17%	226

Other funds holding PRVB

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

EAM Investors's PRVB Position: Q1 2023 in Review

EAM Investors sold out of Provention Bio, Inc. Common Stock (PRVB) in Q1 2023, closing a stake of 276,250 shares — an estimated $2.92M sold.

EAM Investors first reported a position in PRVB in Q2 2019 and held it in 5 quarters. The position peaked at $2.92M in Q4 2022. 182 funds tracked by Wall St. Rank hold PRVB as of Q1 2023.

EAM Investors reported no remaining Provention Bio, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
EAM Investors sold 276,250 Provention Bio, Inc. Common Stock shares in Q1 2023, an estimated $2.92M.
EAM Investors first reported a position in Provention Bio, Inc. Common Stock in Q2 2019 and held it in 5 quarters.
EAM Investors's Provention Bio, Inc. Common Stock position peaked at $2.92M in Q4 2022.
182 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q1 2023.

Based on EAM Investors's 13F filing for Q1 2023, filed 15 May 2023.